Researcher Profile

Rajat Bannerji, MD, PhD

Associate Professor of Medicine, Hematology Oncology
Robert Wood Johnson Medical School
Rutgers, The State University of New Jersey

Rutgers Cancer Institute of New Jersey
195 Little Albany Steeet
New Brunswick, NJ 08901

Phone: (732) 235-7996

Assistant: Bernadette DeSouza
(732) 235-7464

Research Program Alignments

Membership Type: Associate - CCSG

Research Interests

  • Development of novel therapeutics for hematologic malignancies
  • Therapy for high risk, relapsed and refractory chronic lymphocytic leukemia (CLL)
  • Translational studies in CLL to develop biomarkers for treatment response

Selected Publications

The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells. Johnson AJ, Yeh YY, Smith LL, Wagner AJ, Hessler J, Gupta S, Flynn J, Jones J, Zhang X, Bannerji R, Grever MR, Byrd JC. Leukemia. 2012 May 30. doi: 10.1038/leu.2012.144. [Epub ahead of print]

Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. Feldmann G, Mishra A, Bisht S, Karikari C, Garrido-Laguna I, Rasheed Z, Ottenhof NA, Dadon T, Alvarez H, Fendrich V, Rajeshkumar NV, Matsui W, Brossart P, Hidalgo M, Bannerji R, Maitra A, Nelkin BD. Cancer Biol Ther. 2011 Oct 1;12(7):598-609. Epub 2011 Oct 1.

Alemtuzumab-induced syndrome of inappropriate anti-diuretic hormone. Kunz JS, Bannerji R. Leuk Lymphoma. 2005 Apr;46(4):635-7. No abstract available.

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance. Bannerji R, Kitada S, Flinn IW, Pearson M, Young D, Reed JC, Byrd JC. J Clin Oncol. 2003 Apr 15;21(8):1466-71.

Update on the biology of chronic lymphocytic leukemia. Bannerji R, Byrd JC. Curr Opin Oncol. 2000 Jan;12(1):22-9. Review.

Immunotherapy of bladder cancer with cytokine gene-modified tumor vaccines. Saito S, Bannerji R, Gansbacher B, Rosenthal FM, Romanenko P, Heston WD, Fair WR, Gilboa E. Cancer Res. 1994 Jul 1;54(13):3516-20.

Immunotherapy of prostate cancer in the Dunning rat model: use of cytokine gene modified tumor vaccines. Vieweg J, Rosenthal FM, Bannerji R, Heston WD, Fair WR, Gansbacher B, Gilboa E. Cancer Res. 1994 Apr 1;54(7):1760-5.

Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNAs. Rosenthal FM, Cronin K, Bannerji R, Golde DW, Gansbacher B. Blood. 1994 Mar 1;83(5):1289-98.

The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E. J Immunol. 1994 Mar 1;152(5):2324-32.

Regression of bladder tumors in mice treated with interleukin 2 gene-modified tumor cells. Connor J, Bannerji R, Saito S, Heston W, Fair W, Gilboa E. J Exp Med. 1993 Apr 1;177(4):1127-34. Erratum in: J Exp Med 1993 Jun 1;177(6):following 1831.

Antimetastatic vaccination of tumor-bearing mice with two types of IFN-gamma gene-inserted tumor cells. Porgador A, Bannerji R, Watanabe Y, Feldman M, Gilboa E, Eisenbach L. J Immunol. 1993 Feb 15;150(4):1458-70.

Anti-metastatic vaccination of tumor-bearing mice with IL-2-gene-inserted tumor cells. Porgador A, Gansbacher B, Bannerji R, Tzehoval E, Gilboa E, Feldman M, Eisenbach L. Int J Cancer. 1993 Feb 1;53(3):471-7.

Retroviral vector-mediated gamma-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Cancer Res.  1990 Dec 15;50(24): 7820-5.

Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. J Exp Med. 1990 Oct 1;172(4):1217-24.

The content for this Research Profile is maintained by Paul Novembre (